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Preparation and in vivo evaluation of a gel-based nasal delivery 
system for risperidone
The aim of this study was to prepare a nasal gel of risperi-
done and to investigate the pharmacokinetics and relative 
bioavailability of the drug in rats. Compared with oral dos-
ing, the risperidone nasal gel exhibited very fast absorption 
and high bioavailability. Maximal plasma concentration 
(cmax) and the time to reach cmax (tmax) were 15.2 µg mL–1 and 
5 min for the nasal gel, 3.6 µg mL–1and 30 min for the oral 
drug suspension, respectively. Pharmacokinetic parame-
ters such as tmax, cmax and AUC of oral and nasal routes were 
significantly different (p < 0.01). Relative bioavailability of 
the drug nasal preparation to the oral suspension was up to 
1600.0 %. Further, the in vitro effect of the risperidone nasal 
gel on nasal mucociliary movement was also investigated 
using a toad palate model. The risperidone nasal formula-
tion showed mild ciliotoxicity, but the adverse effect was 
temporary and reversible.
Keywords: risperidone, nasal gel, formulation, pharmacoki-
netics, bioavailability, ciliotoxicity
Risperidone is an atypical second-generation antipsychotic drug. It can act as an an-
tagonist to both D2 and 5-HT2 receptors in the brain and is therefore widely used in the 
clinical treatment of positive and negative symptoms in patients with schizophrenia. As 
the compound is water-insoluble and exists in various polymorphic forms, these undesir-
able physiochemical properties of the drug did not only cause some difficulties in pharma-
ceutical formulations, but also led to poor and variable oral bioavailability (1). Today, mar-
keted pharmaceutical products of risperidone are mainly oral formulations such as tablets 
and capsules. Following oral administration, the above preparations often undergo exten-
sive first-pass metabolism, resulting in a slow onset of action and relatively low bioavail-
ability (2). Furthermore, it is very difficult for orally administered risperidone to transport 
and enter the central nervous system (CNS) because of the existence of the blood brain 
barrier (BBB); this often caused poor treatment efficacy of the drug. Therefore, oral dosing 
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Only a few decades ago, the potential of intranasal administration to reach the CNS 
gained great interest and some pharmacological agents following nasal dosing could bypass 
the BBB and enter the CNS. The advantages of nose-to-brain transport include the avoidance 
of systemic circulation, reducing the risk of systemic side effects and hepatic/renal clearing, 
and the possibility of chronic administration. Furthermore, its non-invasiveness, self-ad-
ministration and the rapid onset of action represent an attractive option to further explore 
this route of administration to ultimately improve treatment efficacy of many CNS diseases 
(3). Until now, there have been many drug delivery systems intended for nasal application, 
such as drops, sprays, powders, gels, emulsions, ointments, etc. Among them, drops and 
sprays are not ideal dosage forms because of their shorter residence time after nasal dosing 
and therefore relatively poor absorption and bioavailability. Nasal gels, however, can in-
crease the residence time within the nasal cavity and intensify the contact between nasal 
mucosa and the drug, which facilitates drug absorption and improves bioavailability. They 
are thus one of the most ideal delivery systems for nasal administration (4).
So far, the brain targeting behavior of risperidone nanoemulsion following intranasal 
administration has been confirmed by gamma scintigraphy imaging of rat brain (5). How-
ever, the new drug delivery system of risperidone has many limitations, such as compli-
cated prescribing, poor physicochemical stability, and especially shorter nasal residence 
time. Furthermore, the exact bioavailability of the drug and its nasal ciliotoxicity following 
nasal dosing were not investigated in the literature. Thus, the objective of the present 
study was to prepare a risperidone nasal gel and to further investigate the pharmacokinet-
ics and bioavailability of the drug in rats. Also, the in vitro effect of the risperidone nasal 
preparation on nasal mucociliary movement is explored in this paper as well.
EXPERIMENTAL
Materials
Risperidone of 99.9 % purity was purchased from Beijing Gaobo Pharmaceutical 
Chemical Technology Development Co. (China). Carbopol 940 was purchased from No-
veon Inc. (USA). DMβCD of 98.3 % purity was a gift from Binzhou Zhiyuan Biotechnology 
Co., Ltd. (China). Chlorobutanol of 98.0 % purity was purchased from Sinopharm Chemi-
cal Reagent Co. Ltd. (China). The HPLC grade acetonitrile was obtained from Fisher Scien-
tific (USA). All other chemicals and solvents were of analytical reagent grade and were 
obtained from commercial sources and used as received without further purification. De-
ionized double-distilled water was used throughout.
Preparation of risperidone nasal gel
Optimized prescription of risperidone nasal gel was obtained on the basis of the re-
sults of our previous study and the relevant literature on nasal delivery of medications (6, 
7). The drug formulation was prepared using the cold dissolving method (8). Briefly, an 
exact amount of Carbopol 940 (0.35 %, m/V) was slowly added to approximately 40 mL of 
purified water under continuous stirring, and the resultant dispersion was then kept at 4 
°C overnight for complete swelling, after which it was warmed to room temperature, fol-
lowed by adjustment to pH 6.0 using triethanolamine to obtain a transparent homogenous 
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blank gel. Accurately weighed risperidone (0.5 %, m/V) together with chlorobutanol (0.5 % 
m/V) was dissolved successively in about 20 mL of hot propylene glycol, while the required 
amount of DMβCD (15 %, m/V) was dissolved in an appropriate volume of purified water. 
The two solutions were then mixed to obtain a homogeneous solution and the resultant 
solution was slowly added to the above described blank gel under continuous stirring. 
Finally, the remaining water was added dropwise into the gel to reach the specified vol-
ume of the drug formulation.
Animal experiments
The study was approved by the Institutional Animal Ethics Committee of Affiliated 
Hospital, Inner Mongolia Medical University. All procedures and the care of rats were in 
accordance with the institutional guidelines for animal use in research. Throughout the 
experiment, the animals were housed in plastic cages on corn-cob bedding in a tempera-
ture controlled room (23 ± 2 °C) with a 12 h light/dark cycle. The animals were kept in these 
facilities for at least 1 week before the experiment and fasted for 12 h prior to experiments 
with free access to water. Male Wistar rats (Inner Mongolia University Experimental Ani-
mal Center, Hohhot, China) weighing 250–300 g were used in the study. Twelve rats were 
randomly divided into two groups based on the time of blood sampling, each group hav-
ing six animals. Nasal administration studies were performed according to the method 
described by Gu et al. (9). The test group rats were first anesthetized with urethane given 
intraperitoneally and then placed on their backs, after which the trachea was cannulated 
with a polyethylene tube to stop nasal respiration, and the esophagus was tied to the tube 
to prevent peroral absorption. Risperidone nasal gel was administered at a dose of 3.0 mg 
kg–1 b.m. through a unilateral naris. Blood samples of 0.5 mL each were withdrawn into 
1.5-mL heparinized PE tubes from the retro-orbital plexus at 1, 5, 15, 30, 60, 90, 120, 150,180, 
240 and 360 min immediately after dosing of the nasal gel formulation. For the animals of 
the oral dosing group, risperidone suspension prepared with 0.5 % CMC solution was 
given at a dose of 30 mg kg–1 b.m. via gastric gavage. Blood samples were also collected at 
10, 15, 20, 30, 45, 60, 90, 120, 180, 240 and 360 min following oral dosing. For either nasal or 
oral route, an equal volume of 0.9 % normal saline was given intraperitoneally to rats im-
mediately after each blood sampling. All plasma samples were obtained by centrifuging 
blood samples at 13,000 rpm for 10 min and were stored at –20 °C until analysis.
Risperidone analysis in plasma
Risperidone in rat plasma was quantified by the HPLC-UV method as reported (2), 
with minor modifications. Briefly, 20 µL of 75 µg mL–1 berberine hydrochloride solution 
prepared with methanol (internal standard, IS) and 400 µL of acetonitrile were added suc-
cessively to a 200 µL plasma sample, after which the samples were thoroughly vortexed for 
5 min. The mixture was then centrifuged at 13000 rpm for 10 min and the supernatant 
layer was transferred to a clean 1.5-mL PE tube for drying under a gentle nitrogen steam. 
The residue was reconstituted in 200µL methanol with the help of a vortex mixer, and after 
centrifugation, 25 µL of the supernatant was injected for HPLC analysis. The HPLC system 
consisted of a Shimadzu LC-10AT pump, a SPD-10A ultraviolet-visible detector and a C18 
column (250 × 4.6 mm i.d., 5.0 µm, Japan). The mobile phase was a mixture of acetonitrile 
and 10 mmol L–1 ammonium acetate at a volume ratio of 50/50 (V/V). The flow rate was 1.0 
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mL min–1 and the detection wavelength was set at 280 nm. Quantification was performed 
according to the peak area ratio of the drug to internal standard (Y = Adrug /AIS). The ob-
tained calibration equation (Y = 0.0575c–0.0046, n = 6) showed good linearity over the con-
centration range of 0.5–30.0 µg mL–1 with the correlation coefficient of over 0.99. The lowest 
limit of quantification (LLOQ) for risperidone determination in rat plasma was 0.25 µg 
mL–1. Accuracy of risperidone determination in rat plasma was found to be 106.26 ± 7.75 % 
(n = 9). Within-day and between-day precisions were both lower than 10.0 %. Mean extrac-
tion recovery of risperidone in rat plasma was over 90.0 %.
Pharmacokinetic analysis
Pharmacokinetic analysis was performed by a model-independent method using the 
3P97 pharmacokinetic program, which was issued by the Chinese State Food and Drug 
Administration for pharmacokinetic analysis. The elimination rate constant (Kel) was calcu-
lated by log-linear regression of risperidone concentration and time data during the elimina-
tion phase, and the terminal half-life (t1/2) was calculated as 0.693/Kel. Peak concentration 
(cmax) of the drug in plasma as well as the time to reach cmax (tmax) were observed as raw data. 
The area under the plasma concentration-time curve (AUC0–t) from time zero to the time of 
the last measured concentration (ct) was calculated by means of the linear trapezoidal rule. 
AUC0–∞ was determined by adding AUC0–t, and the extrapolated area was determined by 
calculating ct/Kel. The analysis and comparison of the pharmacokinetic parameters of nasal 
and oral administrations of risperidone were performed using the SPSS statistical software 
(version 22.0, SPSS Inc.). p < 0.05 was taken as statistically significant.
Nasal ciliotoxicity studies
The 0.5 % risperidone nasal gel was freshly prepared before the experiment. To inves-
tigate the effect of DM βCD as well as the preservative alone in the formulation on nasal 
ciliary movement, 15 % DM βCD solution and 0.5 % chlorobutanol solution were also pre-
pared as test solutions. Further, 0.9 % (m/V) normal saline (NS) and 1 % (m/V) sodium de-
oxycholate (a known nasal ciliotoxicity agent) were used as negative and positive controls, 
respectively. Nasal ciliotoxicity studies were carried out using the toad palate model meth-
od as described by Jiang et al. (10). In brief, the upper palate mucosa of toads (30–50 g, Ex-
perimental Animal Center of Inner Mongolia Medical University, China) was dissected 
into small patches of the same size (3 × 3 mm), and then rinsed with saline. Mucosa sam-
ples were spread on a glass slide and instantly treated with a suitable amount of risperi-
done nasal gel or 0.2 mL of other test solutions. After that, they were examined under an 
optical microscope (Olympus, Japan) and the time of ciliary movement (LTCM) was re-
corded. Once the ciliary movement of the mucosa sample ceased, the sample was immedi-
ately rinsed with NS and its LTCM continued to be observed. The total LTCM for the 
sample will be the sum of the two recorded LTCMs.
RESULTS AND DISCUSSION
Risperidone was successfully solubilized by complexation with DMβCD and formu-
lated as a nasal gel preparation. The optimized formulation consisted mainly of the drug, 
Carbopol 940, propylene glycol, DMβCD, chlorobutanol and triethanolamine. The pharma-
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cokinetics and relative bioavailability of the risperidone nasal formulation were investigated 
in rats. Nasal administration studies demonstrated that the drug was very rapidly absorbed 
through the nasal mucosa of rats and its bioavailability was up to about 1600.0 % relative to 
the oral route. The in vitro effect of the drug nasal gel as well as its main excipients on the 
ciliary movement of the toad palate was also explored. The ciliotoxicity of DMβCD as well 
as that of chlorobutanol appeared to be moderate. The whole drug nasal formulation exhib-
ited mild cilitoxicity and the adverse effect was temporary and reversible.
Formulation of risperidone nasal gel
Because of the limited volume of human nasal cavity, lack of adequate aqueous solu-
bility is often the main problem in the development of nasal formulations for poorly water-
soluble drugs. Based on clinical therapeutical doses of marketed oral preparations of ris-
peridone, the nasal gel drug concentration was established to be 0.5 % (m/V), which is 
equivalent to 1 mg of drug per 0.2 g of nasal gel preparation. Since risperidone was re-
ported to include different cyclodextrin derivatives in aqueous solution (11), as solubilizing 
agents, DMβCD was utilized in nasal formulations to prepare a solution-type nasal gel of 
the drug. In addition, this material may also produce an absorption enhancing effect in 
nasal absorption of risperidone, since this effect appears to be most pronounced for 
DMβCD, as reported by Yang et al. (12). Results of the formulation sieving experiment 
performed by our research group have confirmed that a stable solution-type nasal gel of 
risperidone could be obtained only when the DMβCD concentration in the nasal formula-
tion was higher than or equal to 15 %.
Further, according to the bacteriostatic concentration of chlorobutanol often used in 
injections and ophthalmic preparations, concentrations of 0.5 % of the preservative were 
selected for the risperidone nasal preparation. Our previous research proved that risperi-
done showed high oil-water partition coefficient (lipophilicity) and good chemical stabil-
ity when the medium pH was about 6.0, and under the same pH conditions, chlorobutanol 
possessed good chemical stability as well as a bacteriostatic effect. Furthermore, Carbopol 
940 exhibits high viscosity above pH 6.0, and to prevent and reduce irritation to nasal 
mucosa, the ideal pH of a nasal formulation should be within 4.5–6.5. Thus, it seems rea-
sonable that the pH of risperidone nasal gel was finally adjusted to about 6.0. Lastly, the 
obtained nasal gel of risperidone with 0.35 % Carbopol 940 exhibited good appearance, 
spreadability, and rapid in vitro release behavior.
Pharmacokinetic studies
The mean plasma concentration-time profiles of risperidone following nasal and oral 
administrations are illustrated in Fig. 1 while the main pharmacokinetic parameters of the 
drug are summarized in Table I. Very rapid absorption of risperidone after nasal admin-
istration was observed in rats and tmax was only approximately 5 min. In contrast, the 
maximal plasma concentration (cmax) was reached in about 30 min when the drug was 
given to rats orally. The above results indicate that risperidone was more easily absorbed 
in rats through the nasal route than by oral administration. Furthermore, the obtained cmax 
for the nasal route at a dose of 3.0 mg kg–1 was found to be approximately 4 times higher 
than that for oral dosing at a dose of 30 mg kg–1. The relative bioavailability of risperidone 
nasal gel to oral dosing was calculated to be up to 1600.0 %, suggesting that nasal dosing 
resulted in about 15-fold higher extent of drug absorption than the oral route. The reasons 
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for the fast absorption and good bioavailability of risperidone administrated nasally are 
probably as follows. Firstly, higher bioavailability of the nasally administered drug might 
be attributed to the avoidance of hepatic first pass metabolism compared to oral dosing of 
risperidone. Secondly, increased permeability of the nasal mucosa by DMβCD could also 
improve the absorption of the drug, since numerous studies have demonstrated the effi-
cient nasal permeation enhancing effect of cyclodextrin for different drugs (13). Lastly, 
since Carbopol 940 could increase the viscosity of the formulation and form a hydrogen 
bond with the nasal mucosa, this also resulted in increased nasal residence time of the 
formulation and thus improved bioavailability (14).
Nasal cilitoxicity studies
As shown in Table II, the LTCM of the toad palate treated with 0.5 % risperidone nasal 
gel was found to be 50 min, which was far shorter than that of the palate sample treated 
with the negative control 0.9 % saline. However, while the toad palate was rinsed with 0.9 
Fig. 1. Mean plasma concentration-time profiles after administration of 3.0 mg kg–1 of risperidone 
nasal gel and 30 mg kg–1 of the oral drug suspension to rats. Data are represented as mean ± SD (n = 6).
Table I. Pharmacokinetic parameters of risperidone nasal gel in rats using oral suspension as control
Parameters Oral suspension Nasal gel 
tmax (min) 30.0 5.0
cmax (g mL–1) 3.6 ± 1.4 15.2 ± 3.3a
AUC0-t (µg h mL–1) 7.6 ± 4.2 11.5 ± 5.9a
AUC0-∞ (µg h mL–1) 7.9 ± 4.5 12.8 ± 6.6a
Fr (%)  1608.3 %
Data are represented as mean ± SD (n = 6). Oral dose 30 mg kg–1; nasal dose 3.0 mg kg–1.
a p < 0.01, compared to the control.
AUC0–t – area under the plasma concentration-time curve from time zero to the time of last measured concentra-
tion, AUC0–∞– area under the plasma concentration-time curve from time zero to infinite, cmax – peak concentration; 
tmax – time to reach peak concentration.
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% saline immediately after its mucociliary movement ceased, the mucociliary movement of 
the sample was soon restored and lasted about 240 min. Total LTCM for the sample was 
approximately 280 min, which was fairly close to the duration for the 0.9 % saline sample. 
The mucocilliary movement of the toad palate treated with 1 % sodium deoxyycholate solu-
tion stopped almost promptly. In addition, among the additives utilized in the risperidone 
nasal formulation, the preservative 0.5 % chlorobutanol solution showed moderate ciliotox-
icity, but the adverse effect was reversible. Further, the effects of 15 % DMβCD solution on 
the mucociliary movement of the toad palate were found to be similar to the risperidone 
nasal gel. The results were consistent with the report referring to DMβCD (13). In other 
words, DMβCD showed mild ciliotoxicity to mucocilliary movement, but also this adverse 
effect was reversible. Lastly, although the preservative chlorobutanol produced relatively 
moderate ciliotoxcity, the whole nasal gel formulation of the drug showed only mild nasal 
ciliotoxicity and the undesirable effect was temporary and reversible. One of the main rea-
sons might be that the complexation phenomenon of chlorobutanol with DMβCD took place 
in the nasal gel formulation, resulting in the lower-concentration preservative contact with 
the nasal mucosa (15). On the other hand, since the absorption rate of the risperidone gel 
following nasal dosing was very rapid, for example, tmax was only 5 min in the rat pharma-
cokinetic study, it seems reasonable to predict that the in vivo ciliotoxicity of the nasal gel 
formulation should be lower than that observed in the toad palate experiment.
CONCLUSIONS
Nasal dosing of risperidone may be an ideal alternative for the oral route and the drug 
nasal gel preparation will also be a promising novel prescription used in the clinical treat-
ment of schizophrenia, with many advantages such as rapid absorption, onset of action, 
high bioavailability, ease of use, and self-medication. A further study is necessary to inves-
tigate the pharmacokinetics and bioavailability in humans, especially the brain targeting 
characteristics of the risperidone gel following nasal administration. Furthermore, the ef-
fect of the drug nasal preparation on the human nasal ciliary movement and nasal epithe-
lial function remain to be investigated as well. Finally, whether DMβCD in the nasal prep-
Table II. Effect of risperidone nasal gel and its excipients on the toad palate cilia movement





0.9 % NS 287.8 ± 19.4 – 287.8 ± 19.4 100
1 % Sodium deoxycholate 6.6 ± 0.8 0 6.6 ± 0.8b 2.3
0.5 % Risperidone nasal gel 51.0 ± 5.4 224.2 ± 14.6 275.2 ± 16.8a 95.6
15 % DMbCD solution 38.5 ± 3.3 196.0 ± 14.8 234.5 ± 15.5b 81.5
0.5 % Chlorobutanol solution 35.3 ± 1.6 125.6 ± 5.1 165.2 ± 4.8b 55.6
Data are represented as mean ± SD (n = 6).
a p > 0.005, b p < 0.05 or 0.01 compared to the negative control.
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aration will significantly increase the absorption of the drug is still unknown, and a 
transmucosal absorption study is underway in our laboratory.
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